Antares Pharma to Participate in the 2014 RBC Capital Markets’ Global Healthcare Conference
February 19 2014 - 7:00AM
Business Wire
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that LeRoux
Jooste, Senior Vice President and General Manager Pharmaceuticals,
will participate in the RBC Capital Markets’ Global Healthcare
Conference on Wednesday February 26, 2014 at 11:00 am Eastern
Time.
A live webcast will be available via the “Investor Relations”
page of the Antares website, www.antarespharma.com. A replay of the
webcast will also be archived on Antares’ website for 90 days from
the date of participation.
About Antares Pharma
Antares Pharma focuses on self-administered parenteral
pharmaceutical products and topical gel-based medicines. The
Company has received marketing approval from the U.S. Food and Drug
Administration for OTREXUP™ (methotrexate) injection for the
treatment of adults with severe active rheumatoid arthritis,
children with active polyarticular juvenile idiopathic arthritis
and adults with severe recalcitrant psoriasis. Antares Pharma is
also developing VIBEX® QS T for testosterone replacement therapy.
The Company's technology platforms include VIBEX® disposable
Medi-Jet, disposable multi-use pen injectors and Vision™ reusable
needle-free injectors marketed as Tjet® and Zomajet® by Teva
Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals
(Ferring), respectively. Antares Pharma has a multi-product deal
with Teva that includes Tev-Tropin® [somatropin (rDNA origin) for
injection] human growth hormone (hGH), VIBEX® epinephrine and
several other products. Antares Pharma’s partnership with Ferring
includes Zomacton® hGH (somatropin) injection. In the U.S. Antares
has received FDA approval for Gelnique 3%™ (oxybutynin) gel, a
treatment for overactive bladder that is marketed by Actavis.
Elestrin® (estradiol gel) is FDA approved for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause,
and is marketed in the U.S. by Meda Pharma. Antares Pharma has two
facilities in the U.S. The Parenteral Products Group located in
Minneapolis, Minnesota directs the manufacturing and marketing of
the Company’s reusable needle-free injection devices and related
disposables, and develops its disposable pressure-assisted Medi-Jet
and pen injector systems. The Company’s corporate office and
Product Development and Commercial Groups are located in Ewing, New
Jersey.
Antares Pharma, Inc.Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024